GlassScriptPhysician profile
John A Spence
NPI 1497794796
$16,187.97
in general payments reported to CMS, 2019-2025
56 companies · $2,261 in 2025
The $2,261 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $1,921 · 2021: $2,499 · 2022: $2,837 · 2023: $2,383 · 2024: $2,339 · 2025: $2,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,983.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,900.32 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,706.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,236.41 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,043.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $990.21 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $928.79 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $876.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $739.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $640.70 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $640.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $478.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.05 | 2020-2025 | Ofev, Jardiance, Jascayd |
| Allergan, INC. | $443.74 | 2019-2020 | |
| Astellas Pharma US INC | $288.36 | 2020-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $282.75 | 2019-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.